What the FDA labels say about taking them together
Mirtazapine and remifentanil
Remifentanil's FDA label of December 15, 2025 names mirtazapine in its drug interactions section; the mirtazapine label PlainMeds reads does not name remifentanil. The remifentanil label: “The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.”
Check it at the source: the mirtazapine FDA label on DailyMed (effective August 6, 2025, Organon LLC); the remifentanil FDA label on DailyMed (effective December 15, 2025, Mylan Institutional LLC).
What does the mirtazapine label say about remifentanil?
Mirtazapine's label (effective August 6, 2025) does not name remifentanil in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (REMERON), Organon LLC, effective August 6, 2025 (SPL set 98ad1917-a094-44f5-a28f-a64a8cfcd887), via openFDA; the full label on DailyMed
What does the remifentanil label say about mirtazapine?
Remifentanil label, drug interactionsSerotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such …
Remifentanil label, warnings and precautionsSerotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and drugs that impair metabolism of serotonin (including MAO inhibitors, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see Drug Interactions (7) ].
Source: FDA drug label (Ultiva), Mylan Institutional LLC, effective December 15, 2025 (SPL set 4dbcb8f9-1987-4b66-bd2f-d251fda0be10), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Mirtazapine | Remifentanil | |
|---|---|---|
| Labeled for | Depression | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.063 per tablet 15 mg tablet | n/a |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once